Ali Ahmadzade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ali Ahmadzade has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Alireza Hasanzadeh
School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications - David F. Kallmes
Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55905
3 shared publications - Ramanathan Kadirvel
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
3 shared publications - Sherief Ghozy
Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA
3 shared publications - Ahmad Shamabadi
Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications Alzhraa S. Abbas
2 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
Mismatch repair protein deficiency in sebaceous neoplasms and its associations: a two-centre retrospective analysis in Iran
Background: Sebaceous neoplasms in Muir–Torre syndrome (MTS), a subtype of Lynch syndrome, tend to occur before visceral malignancies. MTS is associated with defects in mismatch repair (MMR) proteins, such as MLH1 and MSH2. Early screening for MMR deficiencies in sebaceous neoplasms has been proposed to aid in identifying MTS. Objectives: To determine, using immunohistochemistry (IHC), the prevalence of MMR defects in sebaceous neoplasms in an Iranian cohort. Methods: Samples of sebaceous tumours from tissue registries at two hospitals, collected between March 2014 and March 2019, were analysed using IHC for MLH1 and MSH2. Data analyses were performed using SPSS software version 21. Results: Twenty-five sebaceous neoplasms from 23 individuals were studied. Overall, 12 (48%) samples showed abnormal IHC results. Specifically, six (24%) samples had MSH2 deficiency, three (12%) exhibited MLH1 deficiency and another three (12%) were deficient in both. Two patients each had two sebaceous neoplasms; in one patient, both tumours showed MSH2 deficiency, while in the other, both tumours exhibited loss of expression for both MMR proteins. Neither tumour type nor patient sex was linked to MMR deficiency. However, tumours outside the head and neck region were significantly associated with MSH2 deficiency. Additionally, younger patients had a higher prevalence of MSH2 deficiency. Conclusions: Multiple sebaceous tumours, tumours presenting at a younger age and tumours located outside the head and neck area could be the most important predictors of IHC abnormalities. After validation by larger future studies, these predictors should be considered for targeted MTS screening strategies.
- 7 September 2026
- Published by Oxford University Press (OUP) in Skin Health and Disease
Open AccessMismatch repair protein deficiency in sebaceous neoplasms and its associations: a two-centre retrospective analysis in Iran
Background: Sebaceous neoplasms in Muir–Torre syndrome (MTS), a subtype of Lynch syndrome, tend to occur before visceral malignancies. MTS is associated with defects in mismatch repair (MMR) proteins, such as MLH1 and MSH2. Early screening for MMR deficiencies in sebaceous neoplasms has been proposed to aid in identifying MTS. Objectives: To determine, using immunohistochemistry (IHC), the prevalence of MMR defects in sebaceous neoplasms in an Iranian cohort. Methods: Samples of sebaceous tumours from tissue registries at two hospitals, collected between March 2014 and March 2019, were analysed using IHC for MLH1 and MSH2. Data analyses were performed using SPSS software version 21. Results: Twenty-five sebaceous neoplasms from 23 individuals were studied. Overall, 12 (48%) samples showed abnormal IHC results. Specifically, six (24%) samples had MSH2 deficiency, three (12%) exhibited MLH1 deficiency and another three (12%) were deficient in both. Two patients each had two sebaceous neoplasms; in one patient, both tumours showed MSH2 deficiency, while in the other, both tumours exhibited loss of expression for both MMR proteins. Neither tumour type nor patient sex was linked to MMR deficiency. However, tumours outside the head and neck region were significantly associated with MSH2 deficiency. Additionally, younger patients had a higher prevalence of MSH2 deficiency. Conclusions: Multiple sebaceous tumours, tumours presenting at a younger age and tumours located outside the head and neck area could be the most important predictors of IHC abnormalities. After validation by larger future studies, these predictors should be considered for targeted MTS screening strategies.
- 7 April 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (10) , 2026-2032
MR Imaging versus Noncontrast CT for Selecting Patients with Acute Ischemic Stroke of Large Vessel Occlusion for Endovascular Thrombectomy: A Systematic Review and Meta-Analysis
BACKGROUND: Neuroimaging in the acute phases after the onset of the stroke symptoms is necessary to determine large vessel occlusion presence as well as the extent of the ischemic insult before deeming eligibility for endovascular thrombectomy (EVT). PURPOSE: To evaluate the clinical outcomes in acute ischemic stroke patients selected for EVT based on initial imaging; non-contrast computed tomography (NCCT) compared to those selected using magnetic resonance imaging (MRI). DATA SOURCES: PubMed, Embase, Scopus, and Web of Science were searched from inception to August, 2024. STUDY SELECTION: We included observational studies comparing functional independence (mRS 0-2), successful reperfusion (TICI 2b-3), symptomatic intracerebral hemorrhage (sICH) or mortality in patients selected for EVT using NCCT±CT angiography versus MRI ±MR angiography. We excluded studies that used perfusion imaging in their patient selection for EVT. DATA ANALYSIS: Data were pooled using random-effects model, and heterogeneity was assessed using I2 statistics. A subgroup analysis was performed to determine the effect of treatment window (6h from last known well). The quality of eligible studies was assessed by using Newcastle Ottawa Scale. DATA SYNTHESIS: Seven studies (n=3,940 patients) met the inclusion criteria. Two studies had low risk of bias and others had some concerns. Patients with MRI selection showed better chances of functional independence (Odds ratio (OR), 1.85 [95% CI, 1.28-2.67]; p2=45%), lower rates of sICH (OR 0.59, 95% CI 0.39–0.89; p=0.01, I2=0%), reduced 90 days mortality (OR 0.63, 95% CI 0.51–0.78; p2=0%) and no difference in successful reperfusion (OR 0.99, 95% CI 0.62–1.58; p=0.95, I2=0%) compared to NCCT in patients treated within 6 hours of stroke onset. There were no significant differences in any endpoints between MRI and NCCT for patients treated beyond 6 hours. LIMITATIONS: Our meta-analysis comprised only observational studies, with different populations and imaging protocols limiting the strength of the conclusions. CONCLUSIONS: Within the crucial <6-hour window, MRI9s superior patient selection justifies its use despite longer acquisition times. Beyond 6 hours, the focus should shift to rapid EVT access rather than imaging modality choice, as the benefits of MRI diminish. ABBREVIATIONS: EVT = Endovascular Thrombectomy; IVT = Intravenous Thrombolysis; AIS-LVO = Acute Ischemic Stroke-Large Vessel Occlusion
- 7 April 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (10) , 2026-2032
MR Imaging versus Noncontrast CT for Selecting Patients with Acute Ischemic Stroke of Large Vessel Occlusion for Endovascular Thrombectomy: A Systematic Review and Meta-Analysis
BACKGROUND: Neuroimaging in the acute phases after the onset of the stroke symptoms is necessary to determine large vessel occlusion presence as well as the extent of the ischemic insult before deeming eligibility for endovascular thrombectomy (EVT). PURPOSE: To evaluate the clinical outcomes in acute ischemic stroke patients selected for EVT based on initial imaging; non-contrast computed tomography (NCCT) compared to those selected using magnetic resonance imaging (MRI). DATA SOURCES: PubMed, Embase, Scopus, and Web of Science were searched from inception to August, 2024. STUDY SELECTION: We included observational studies comparing functional independence (mRS 0-2), successful reperfusion (TICI 2b-3), symptomatic intracerebral hemorrhage (sICH) or mortality in patients selected for EVT using NCCT±CT angiography versus MRI ±MR angiography. We excluded studies that used perfusion imaging in their patient selection for EVT. DATA ANALYSIS: Data were pooled using random-effects model, and heterogeneity was assessed using I2 statistics. A subgroup analysis was performed to determine the effect of treatment window (6h from last known well). The quality of eligible studies was assessed by using Newcastle Ottawa Scale. DATA SYNTHESIS: Seven studies (n=3,940 patients) met the inclusion criteria. Two studies had low risk of bias and others had some concerns. Patients with MRI selection showed better chances of functional independence (Odds ratio (OR), 1.85 [95% CI, 1.28-2.67]; p2=45%), lower rates of sICH (OR 0.59, 95% CI 0.39–0.89; p=0.01, I2=0%), reduced 90 days mortality (OR 0.63, 95% CI 0.51–0.78; p2=0%) and no difference in successful reperfusion (OR 0.99, 95% CI 0.62–1.58; p=0.95, I2=0%) compared to NCCT in patients treated within 6 hours of stroke onset. There were no significant differences in any endpoints between MRI and NCCT for patients treated beyond 6 hours. LIMITATIONS: Our meta-analysis comprised only observational studies, with different populations and imaging protocols limiting the strength of the conclusions. CONCLUSIONS: Within the crucial <6-hour window, MRI9s superior patient selection justifies its use despite longer acquisition times. Beyond 6 hours, the focus should shift to rapid EVT access rather than imaging modality choice, as the benefits of MRI diminish. ABBREVIATIONS: EVT = Endovascular Thrombectomy; IVT = Intravenous Thrombolysis; AIS-LVO = Acute Ischemic Stroke-Large Vessel Occlusion
- 27 February 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (3) , 510-516
Initial Experience with the Pipeline Vantage Flow Diverter for Intracranial Aneurysms: A Systematic Review and Meta-Analysis
Background: The Pipeline Vantage Flow diverter (Vantage) is the latest generation of Pipeline flow diverters introducing Cobalt-chronium drawn-filled tubing and 48 to 68 wires. Purpose: We report the initial safety and efficacy of Vantage in treating intracranial aneurysms in the published literature. Data Sources: A systematic review and meta-analysis was conducted according to established protocols. Searches were conducted in PubMed, Scopus, Web-of-Science, and Embase databases up to December 2023. Original studies reporting treatment outcomes for intracranial aneurysms using Vantage in more than five patients were included. Study Selection: Pooled data from 5 studies (373 patients, 418 aneurysms) were analyzed. Data Analysis: Outcomes of interest were: technical success, occlusion rates, complication outcomes and mortality. Data Synthesis: A technical success rate of 99.2% (95% CI: 98.29%–100%) was found. In unruptured cases, success rate was 378/383 (99.6%) versus 17/20 (85.0%) in ruptured cases (P < .01). Complete occlusion rate was 74.3% (95% CI: 67.43%–80.59%), with no significant difference between ruptured and unruptured cases (P = 0.72); median of follow up 6 months. Overall mortality rate was 1.2% (95% CI: 0.01%–3.64%), significantly higher in ruptured (18.6%; 95% CI: 5.13%–36.26%) versus unruptured cases (0.23%; 95% CI: 0%–1.36%) (P < 0.01). Hemorrhagic complications occurred at 1% (95% CI: 0%–3.36%) pooled rate. Thromboembolic complications were reported at 6.1% (95% CI: 2.60%–10.73%), decreasing to 4.35% (95% CI: 1.91%–7.54%) after excluding one outlier study. Limitations: Only five studies, some with small number of patients, were included in this meta-analysis which may limit the generalizability of our findings. The absence of long term follow-up also limits the assessment of treatment durability. Conclusions: In this meta-analysis, we found that Vantage initial experience is similar to previous version of the Pipeline Embolization Device in terms of safety and efficacy for treatment of intracranial aneurysms, in particular unruptured aneurysms. Further prospective and comparative studies with patient outcome data specific to aneurysm location are needed to confirm the safety and efficacy of Vantage.
- 27 February 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (3) , 510-516
Initial Experience with the Pipeline Vantage Flow Diverter for Intracranial Aneurysms: A Systematic Review and Meta-Analysis
Background: The Pipeline Vantage Flow diverter (Vantage) is the latest generation of Pipeline flow diverters introducing Cobalt-chronium drawn-filled tubing and 48 to 68 wires. Purpose: We report the initial safety and efficacy of Vantage in treating intracranial aneurysms in the published literature. Data Sources: A systematic review and meta-analysis was conducted according to established protocols. Searches were conducted in PubMed, Scopus, Web-of-Science, and Embase databases up to December 2023. Original studies reporting treatment outcomes for intracranial aneurysms using Vantage in more than five patients were included. Study Selection: Pooled data from 5 studies (373 patients, 418 aneurysms) were analyzed. Data Analysis: Outcomes of interest were: technical success, occlusion rates, complication outcomes and mortality. Data Synthesis: A technical success rate of 99.2% (95% CI: 98.29%–100%) was found. In unruptured cases, success rate was 378/383 (99.6%) versus 17/20 (85.0%) in ruptured cases (P < .01). Complete occlusion rate was 74.3% (95% CI: 67.43%–80.59%), with no significant difference between ruptured and unruptured cases (P = 0.72); median of follow up 6 months. Overall mortality rate was 1.2% (95% CI: 0.01%–3.64%), significantly higher in ruptured (18.6%; 95% CI: 5.13%–36.26%) versus unruptured cases (0.23%; 95% CI: 0%–1.36%) (P < 0.01). Hemorrhagic complications occurred at 1% (95% CI: 0%–3.36%) pooled rate. Thromboembolic complications were reported at 6.1% (95% CI: 2.60%–10.73%), decreasing to 4.35% (95% CI: 1.91%–7.54%) after excluding one outlier study. Limitations: Only five studies, some with small number of patients, were included in this meta-analysis which may limit the generalizability of our findings. The absence of long term follow-up also limits the assessment of treatment durability. Conclusions: In this meta-analysis, we found that Vantage initial experience is similar to previous version of the Pipeline Embolization Device in terms of safety and efficacy for treatment of intracranial aneurysms, in particular unruptured aneurysms. Further prospective and comparative studies with patient outcome data specific to aneurysm location are needed to confirm the safety and efficacy of Vantage.
- 21 February 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (9) , 1821-1829
Impact of Smoking on Recurrence and Angiographic Outcomes after Endovascular Treatment of Intracranial Aneurysms: A Systematic Review and Meta-Analysis
BACKGROUND: Cerebral aneurysm recurrence serves as a significant endpoint for assessing the efficacy of various endovascular treatment strategies. The impact of smoking on outcomes such as aneurysm occlusion, recurrence, and recanalization remains unclear due to conflicting evidence. PURPOSE: To systematically evaluate the role of smoking in influencing angiographic outcomes following endovascular treatment of intracranial aneurysms. DATA SOURCES: Comprehensive searches were conducted in PubMed, Embase, Scopus, and Web of Science STUDY SELECTION: This systematic review and meta-analysis followed PRISMA guidelines to identify relevant studies assessing smoking9s impact on intracranial aneurysms following endovascular treatment. DATA ANALYSIS: Studies were screened, selected, and assessed for risk of bias using appropriate checklists. Data on complete and adequate aneurysm occlusion, and recurrence/recanalization rates were extracted. Random-effects meta-analyses calculated risk ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was measured using the I2 statistic. DATA SYNTHESIS: A total of 26 studies, encompassing 6,031 patients, met the inclusion criteria. Smokers had higher rates of complete aneurysm occlusion (RR 1.12, 95% CI 1.06–1.19; p < 0.01). Subgroup analysis revealed that smokers undergoing flow diversion exhibited a higher rate of complete occlusion (RR 1.14, 95% CI 1.07–1.21; p < 0.01). However, for patients undergoing coiling, there was no significant difference in complete occlusion rates between smokers and non-smokers (RR 1.00, 95% CI 0.83– 1.20; p = 0.46). Recurrence/recanalization rates were similar between smokers and non-smokers: RR 1.17, 95% CI 0.93–1.47; p = 0.20, and the rate of aneurysm retreatment did not differ between the smokers and non-smokers: RR 0.82, 95% CI 0.59–1.13; p =0.23. LIMITATIONS: Heterogeneity in definitions of smoking status, variations in follow-up durations, short follow up, retrospective nature of studies. CONCLUSIONS: Smoking status does not significantly impact aneurysm recanalization or retreatment after endovascular repair. However, the impact of smoking on complete occlusion rate might differ based on the type of device used for treatment. Histological and molecular factors may contribute to varied outcomes, highlighting the necessity for further research to understand smoking9s role in aneurysm healing. Clinically, patients should be advised about the risks of smoking, though current evidence suggests that smoking cessation may not consistently affect treatment efficacy. ABBREVIATIONS: sAH = subarachnoid hemorrhage; RROC = Raymond-Roy occlusion classification.
- 21 February 2025
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (9) , 1821-1829
Impact of Smoking on Recurrence and Angiographic Outcomes after Endovascular Treatment of Intracranial Aneurysms: A Systematic Review and Meta-Analysis
BACKGROUND: Cerebral aneurysm recurrence serves as a significant endpoint for assessing the efficacy of various endovascular treatment strategies. The impact of smoking on outcomes such as aneurysm occlusion, recurrence, and recanalization remains unclear due to conflicting evidence. PURPOSE: To systematically evaluate the role of smoking in influencing angiographic outcomes following endovascular treatment of intracranial aneurysms. DATA SOURCES: Comprehensive searches were conducted in PubMed, Embase, Scopus, and Web of Science STUDY SELECTION: This systematic review and meta-analysis followed PRISMA guidelines to identify relevant studies assessing smoking9s impact on intracranial aneurysms following endovascular treatment. DATA ANALYSIS: Studies were screened, selected, and assessed for risk of bias using appropriate checklists. Data on complete and adequate aneurysm occlusion, and recurrence/recanalization rates were extracted. Random-effects meta-analyses calculated risk ratios (ORs) with 95% confidence intervals (CIs). Heterogeneity was measured using the I2 statistic. DATA SYNTHESIS: A total of 26 studies, encompassing 6,031 patients, met the inclusion criteria. Smokers had higher rates of complete aneurysm occlusion (RR 1.12, 95% CI 1.06–1.19; p < 0.01). Subgroup analysis revealed that smokers undergoing flow diversion exhibited a higher rate of complete occlusion (RR 1.14, 95% CI 1.07–1.21; p < 0.01). However, for patients undergoing coiling, there was no significant difference in complete occlusion rates between smokers and non-smokers (RR 1.00, 95% CI 0.83– 1.20; p = 0.46). Recurrence/recanalization rates were similar between smokers and non-smokers: RR 1.17, 95% CI 0.93–1.47; p = 0.20, and the rate of aneurysm retreatment did not differ between the smokers and non-smokers: RR 0.82, 95% CI 0.59–1.13; p =0.23. LIMITATIONS: Heterogeneity in definitions of smoking status, variations in follow-up durations, short follow up, retrospective nature of studies. CONCLUSIONS: Smoking status does not significantly impact aneurysm recanalization or retreatment after endovascular repair. However, the impact of smoking on complete occlusion rate might differ based on the type of device used for treatment. Histological and molecular factors may contribute to varied outcomes, highlighting the necessity for further research to understand smoking9s role in aneurysm healing. Clinically, patients should be advised about the risks of smoking, though current evidence suggests that smoking cessation may not consistently affect treatment efficacy. ABBREVIATIONS: sAH = subarachnoid hemorrhage; RROC = Raymond-Roy occlusion classification.
- Open Access
- 10 July 2023
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 25 (1) , 50-63
Suicidality risk after using cannabis and cannabinoids: An umbrella review
The increasing prevalence and burden of suicide have led to numerous studies to identify its risk factors. Cannabis is the most common illicit substance detected in suicide victims’ toxicology tests. This study aims to identify and appraise systematic reviews investigating suicidality after using cannabis and cannabinoids. Seven databases and two registries were searched without restrictions for systematic reviews investigating cannabis effects on suicidality. AMSTAR-2 was used for quality assessment and corrected covered area and citation matrix were used to determine overlap. Twenty-five studies were included, of which 24 were on recreational use and one was on therapeutic use. Only three of the studies on recreational use reported no effect or inconsistent results. Evidence generally showed a positive association between cannabis use and suicidal ideation and attempt among the general population, military veterans, and bipolar or major depression patients. A bidirectional causal association between cannabis and suicidal ideation was also mentioned. Moreover, a younger age of initiation, long-term use, and heavy consumption were reported to be associated with even worse suicidal outcomes. On the contrary, current evidence indicates that the therapeutic cannabis is safe. In conclusion, the literature supports the cannabis-suicidality association in recreational use but considers cannabidiol safe for treatment. Further studies with quantitative and interventional approaches are recommended.
- 10 July 2023
- Published by Taylor & Francis in Dialogues in clinical neuroscience
- Vol. 25 (1) , 50-63
Open AccessSuicidality risk after using cannabis and cannabinoids: An umbrella review
The increasing prevalence and burden of suicide have led to numerous studies to identify its risk factors. Cannabis is the most common illicit substance detected in suicide victims’ toxicology tests. This study aims to identify and appraise systematic reviews investigating suicidality after using cannabis and cannabinoids. Seven databases and two registries were searched without restrictions for systematic reviews investigating cannabis effects on suicidality. AMSTAR-2 was used for quality assessment and corrected covered area and citation matrix were used to determine overlap. Twenty-five studies were included, of which 24 were on recreational use and one was on therapeutic use. Only three of the studies on recreational use reported no effect or inconsistent results. Evidence generally showed a positive association between cannabis use and suicidal ideation and attempt among the general population, military veterans, and bipolar or major depression patients. A bidirectional causal association between cannabis and suicidal ideation was also mentioned. Moreover, a younger age of initiation, long-term use, and heavy consumption were reported to be associated with even worse suicidal outcomes. On the contrary, current evidence indicates that the therapeutic cannabis is safe. In conclusion, the literature supports the cannabis-suicidality association in recreational use but considers cannabidiol safe for treatment. Further studies with quantitative and interventional approaches are recommended.
- Open Access
- 19 June 2022
- Published by Knowledge E DMCC in Iranian Journal of Psychiatry
- Vol. 17 (3) , 320-340
Ketamine and other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials
Objective: Available treatments of depression have limited efficacy and unsatisfactory remission rates. This study aims to review randomized controlled trials (RCTs) investigating effects of glutamate receptor modulators in treating patients with resistant depression. Method: The study protocol was registered in PROSPERO (CRD42021225516). Scopus, ISI Web of Science, Embase, Cochrane Library, Google Scholar, and three trial registries were searched up to September 2020 to find RCTs evaluating glutamate receptor modulators for resistant depression. The difference between intervention and control groups in changing depression scores from baseline to endpoint was considered the primary outcome. Version 2 of the Cochrane risk-of-bias tool for randomized trials was used to assess the quality of the RCTs. No funding was received. Results: Thirty-eight RCTs were included. Based on the included studies, compelling evidence was found for ketamine (with or without electroconvulsive therapy, intravenous or other forms), nitrous oxide, amantadine, and rislenemdaz (MK-0657); the results for MK-0657, amantadine, and nitrous oxide were only based on one study for each. Lithium, lanicemine, D-cycloserine, and decoglurant showed mixed results for efficacy, and, riluzole, and 7-chlorokynurenic acid were mostly comparable to placebo. A limited number of studies were available that addressed drugs other than ketamine. Conclusion: The study cannot determine the difference between statistical and clinical significance between the agents and placebo due to high heterogeneity among the RCTs. Nevertheless, ketamine could be used as an efficacious drug in TRD; still, additional studies are needed to delineate the optimum dosage, duration of efficacy, and intervals. Further studies are also recommended on the effectiveness of glutamatergic system modulators other than ketamine on treatment-resistant depression.
- 19 June 2022
- Published by Knowledge E DMCC in Iranian Journal of Psychiatry
- Vol. 17 (3) , 320-340
Open AccessKetamine and other Glutamate Receptor Modulating Agents for Treatment-Resistant Depression: A Systematic Review of Randomized Controlled Trials
Objective: Available treatments of depression have limited efficacy and unsatisfactory remission rates. This study aims to review randomized controlled trials (RCTs) investigating effects of glutamate receptor modulators in treating patients with resistant depression. Method: The study protocol was registered in PROSPERO (CRD42021225516). Scopus, ISI Web of Science, Embase, Cochrane Library, Google Scholar, and three trial registries were searched up to September 2020 to find RCTs evaluating glutamate receptor modulators for resistant depression. The difference between intervention and control groups in changing depression scores from baseline to endpoint was considered the primary outcome. Version 2 of the Cochrane risk-of-bias tool for randomized trials was used to assess the quality of the RCTs. No funding was received. Results: Thirty-eight RCTs were included. Based on the included studies, compelling evidence was found for ketamine (with or without electroconvulsive therapy, intravenous or other forms), nitrous oxide, amantadine, and rislenemdaz (MK-0657); the results for MK-0657, amantadine, and nitrous oxide were only based on one study for each. Lithium, lanicemine, D-cycloserine, and decoglurant showed mixed results for efficacy, and, riluzole, and 7-chlorokynurenic acid were mostly comparable to placebo. A limited number of studies were available that addressed drugs other than ketamine. Conclusion: The study cannot determine the difference between statistical and clinical significance between the agents and placebo due to high heterogeneity among the RCTs. Nevertheless, ketamine could be used as an efficacious drug in TRD; still, additional studies are needed to delineate the optimum dosage, duration of efficacy, and intervals. Further studies are also recommended on the effectiveness of glutamatergic system modulators other than ketamine on treatment-resistant depression.